Date: 2015-10-01
Type of information: Licensing agreement
Compound: GlymaxX® Antibody Glyco-Engineering technology
Company: ProBioGen (Germany) Tizona Therapeutics (USA - CA)
Therapeutic area: Technology - Services - Cancer - Oncology
Type agreement: licensing developement services contract
Action mechanism: ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity is an important antibody function leading to selectively killing target cells, i.e. cancer cells or pathogen-infected cells. ADCC enhancement has the potential to increase the therapeutic effect and/or to greatly reduce antibody dosage requirements, resulting in fewer side-effects and treatment costs. The absence of fucose enhances ADCC. The GlymaxX® technology, developed by ProBioGen, prevents the synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which eliminates the producer cells’ fucose biosynthesis pathway. GlymaxX® is universally applicable to different Chinese hamster ovary, or CHO, hosts and all other eukaryotic cell species. It can be applied in a few weeks to any existing antibody producer cell line, can be used in the context of ProBioGen’s pre-engineered GlymaxX® host cells, or can be introduced into entire animal cell expression platforms by modifying the host cell line. ProBioGen offers its GlymaxX® technology royalty-free as a service or as an individual license.
Disease:
Details: * On October 1, 2015, ProBioGen and Tizona Therapeutics have signed a commercial license and service agreement for cell line and process development. Under the Agreement ProBioGen will develop Tizona’s immuno-oncology antibody up to GMP manufacturing, applying ProBioGen’s proprietary GlymaxX® cell line to boost the antibody’s ADCC anti-tumor activity. The program will follow ProBioGen’s integrated and accelerated development path which allows selecting superior, stable producer clones with robust and excellent process features in a significantly reduced time, facilitating the earlier onset of clinical trials. Manufacturing of clinical study material will be conducted at ProBioGen’s new facility which will house two additional 1,000L single-use bioreactors in its GMP suites.
Financial terms:
Latest news:
